Our People

Viralytics Ltd's Board and Management Team have extensive experience in the areas of biotechnology research, product development and financial management in the healthcare industry. Their combined skills have positioned the company to grow Viralytics through acquisitions of new projects and alliances for product development.

Board of Directors

Paul Hopper, Independent Chairman (Non-Executive)
Mr. Hopper is based in Los Angeles, CA and has over 20 years experience in the management and funding of biotechnology and healthcare public companies. He has been involved in over $200 million in equity and debt financings in Australia, Asia, the U.S. and Europe.

His sector experience includes anti-bacterials, medical devices, antibodies, inflammation and oncology, with a particular emphasis on cancer vaccines. Mr. Hopper is a director of Boston-based pSivida Corp (NASDAQ:PSDV), a drug delivery technology company, and Somnomed Limited (ASX:OM), a global manufacturer and marketer of dental devices for sleep disorders. Mr. Hopper is Managing Director at the Los Angeles merchant bank, Cappello Group. He has served as Chairman or Director of many listed biotech and healthcare companies, including Bone Medical Limited, Advanced Biotherapy, Inc., Australian Cancer Technology Limited and Medaire Ltd. He was the co-founder and Managing Director of Alpha Healthcare Limited.
Peter Molloy, Independent Director (Non-Executive)
Mr. Molloy joined the Viralytics board in September 2008. He is a successful Australian pharmaceutical and biotechnology industry executive who is now a U.S.-based industry consultant. Based in La Jolla, CA, Mr. Molloy most recently served as the Managing Director and CEO of Biota Holdings Limited (2002-2005), Australia’s premier anti-viral drug development company. Under his leadership, this company grew from $25 million to $250 million in market value. Biota Holdings was recognized as Australia’s top industry performer in the November 2005 issue of PWC’s BioForum magazine.

He previously served as President and CEO of SLIL Biomedical Corp., a Madison, Wisconsin-based cancer and viral research company, Managing Director and CEO of Florigene Limited, a Melbourne-based company focused on the genetic modifications of plants, and as President of Moleculon Inc, a Boston-based transdermal drug delivery company. Mr. Molloy spent 17 years as a marketing executive for Pharmacia, including his last role as Vice President of Strategic Marketing. At Pharmacia, he evaluated new drug candidates and was responsible for the launch and marketing strategy of more than 50 new drugs across 23 countries. Mr. Molloy holds an undergraduate degree in Microbiology and Biochemistry from the University of Melbourne and an MBA from the University of Adelaide.
Bryan Dulhunty, Managing Director & CEO
Mr Dulhunty is a Chartered Accountant with over 30 years experience. Mr Dulhunty has been involved in the biotechnology industry for over 15 years in both listed and non-listed public companies at a senior level with particular emphasis on emerging companies and companies in early stage commercialisation.

Mr Dulhunty is a specialist in financial and corporate compliance matters. Mr Dulhunty formed CoSA Pty Ltd in 2000 to provide financial management and financial assurance to emerging biotech companies. This role resulted in the appointment of Mr Dulhunty to a number of Board and senior management consultant roles within the biotech industry.

Mr Dulhunty’s prior experience was with a major international accounting firm and one of the world’s largest international companies
.
Dr. Phillip Altman, Non-Executive Director
Dr. Altman is a well-known Australian authority on clinical trials and regulatory affairs with more than 30 years experience. He has held senior management positions with several multinational companies, including Merrell-Dow, Hoechst, Roussel and GD Searle. Dr. Altman founded his own company, Pharmaco Pty. Ltd., one of Australia’s first contract research organizations, and served as Senior Industry Consultant. He has been involved in over 100 clinical trials (Phase I through Phase IV) and has been personally responsible for the marketing approval of numerous new drugs and dosage forms since beginning his career in the pharmaceutical industry in 1974.

Dr. Altman is a graduate of Sydney University with an Honors degree in Pharmacy, Master of Science and Doctor of Philosophy (pharmacology and pharmaceutical chemistry) degrees. He co-founded and is a life member of ARCS (Association of Regulatory and Clinical Scientists to the Australian Pharmaceutical Industry).

Management

Darren Shafren, Chief Scientific Officer
Professor Shafren is Associate Professor of Virology in the Faculty of Health, University of Newcastle, Australia and has over 20 years experience in basic and molecular virology. Dr. Shafren is the founding inventor of the oncolytic virus technology which Viralytics acquired in 2006.
Stephen Goodall, Chief Operating Officer
Mr. Goodall has specialised in biotechnology product development for over 25 years, including process and product development, facilities design and construction and international registration of medical products. He has been a senior executive and director of both public and unlisted biotechnology companies. He is based at the Company’s Newcastle facilities and is responsible for day-to-day operations, GMP virus manufacture and FDA regulatory discussions.
Gavin D Clark, Business Development Representative
Mr. Clark, based in the U.K., has a prolific background in international partnering, including licensing, collaborations and mergers and acquisitions. Most recently, he co-founded Dublin-based Procela Partners. Since 2002, he has provided business advice to numerous biotech companies, including Acumen Pharmaceuticals, Pintex, Pliva dd and PowderMed. Mr. Clark previously served as Director of Global Licensing – Infectious Diseases at Glaxo Wellcome and as VP Business Development at Tibote until its acquisition by Johnson & Johnson.
Sarah Prince, Company Secretary
Ms Prince is a solicitor for Company Matters Pty. Ltd. and also serves as Company Secretary for National Leisure & Gaming Limited and Palau Pacific Exploration Pty. Ltd.